CD37

Cohort 7 of the clinical trial of HDP-101 in multiple myeloma safe and well tolerated Cohort 8 expected to start soon Clinical development of the second ADC program HDP-102 in patients with non-Hodgkin lymphoma (NHL) has started Amendment of contract with HealthCare Royalty; payment of USD 20 million significantly extends cash reach Ladenburg, Germany, 24 April 2025 - Heidelberg Pharma AG (FSE: HPHA) today reported on the first three months of fiscal year 2025 (1 December 2024 – 28 February 2025) and the Group’s financial figures. Professor Andreas Pahl, Chief Executive Officer of Heidelberg Pharma AG, commented: “We are pleased that our lead ATAC candidate, HDP-101, has again proven to be safe and well tolerated in cohort 7 at a dose of 112.50 µg/kg. We have not yet reached the maximum tolerated dose and are continuing the dose escalation as planned. This supports that we are developing an ATAC with an attractive therapeutic window. Particularly encouraging is the persistently stable condition of a patient with complete remission. All this allows us to be very optimistic about the start of cohort 8. In addition, we are reaching the next milestone in our pipeline – clinical testing of our second ATAC program HDP-102 has started.” Walter Miller, Chief Financial Officer of Heidelberg Pharma AG, added: “Not only are our clinical projects making promising progress, but our financing activities have also been extremely successful. As a result of the amendment of the license agreement with HealthCare Royalty, we received a further payment of USD 20 million at the beginning of March. This and an expected payment of USD 70 million upon market approval of Telix’ TLX250-CDx extend our cash reach into 2027 based on current planning. We are pleased with this solid financial footing as we advance the development of our product portfolio.” HDP-101 (BCMA ATAC) development program: The Amanitin-based ADC candidate HDP-101 is being evaluated in a Phase I/IIa clinical trial for the treatment of relapsed or refractory multiple myeloma. The first seven patient cohorts and dose levels have been completed. After completion of cohort 7, the Safety Review Committee (SRC) concluded that the 112.50 µg/kg dose used is safe and well tolerated and that the study can continue with cohort 8 at a dose of 140 µg/kg. Analogous to the dosing regimen of cohort 7, patients in cohort 8 will also be dosed in two different arms. As long as patients in cohort 7 do not progress, they will continue to be treated with the previous dose level. The analysis of the data is ongoing. The presentation of new clinical data is planned for the EHA Congress, a conference of the European Hematology Association, in Milan, Italy, in mid-June. The study has shown very encouraging results so far, including a complete remission in a patient from cohort 5 who had been heavily pretreated with different therapies and was then treated continuously with HDP-101 alone. In addition, several patients showed promising biological activity and objective improvements, which underscores the potential of HDP-101 as a treatment option for patients with multiple myeloma. Development program HDP-102: HDP-102 is an ATAC targeting CD37 that is expressed on B-cell lymphoma cells. Heidelberg Pharma plans to develop HDP-102 for non-Hodgkin lymphoma (NHL). With over 550,000 new cases diagnosed each year worldwide, NHL is one of the more common types of cancer. Heidelberg Pharma has received all the necessary approvals to start the clinical trial and expects the dosing of the first patient shortly. The trial will be conducted in the Republic of Moldova, Israel and selected EU countries. New preclinical data were presented at the American Association for Cancer Research (AACR) 2024 Annual Meeting. The candidate showed in-vivo excellent anti-tumor efficacy and good tolerability after a single administration. TLX250-CDx - Partnered radio-pharmaceutical program on the road to market approval In December 2024, the Australian partner Telix Pharmaceuticals Limited, Melbourne, (Telix) completed the submission of the revised Biologics License Application (BLA) for its PET imaging agent TLX250-CDx to the US Food and Drug Administration (FDA). On 26 February 2025, Telix announced that the FDA had accepted the BLA for TLX250-CDx, granted a Priority Review, and provided a Prescription Drug User Fee Act (PDUFA) date of 27 August 2025. Amendment of the royalty purchase agreement with HealthCare Royalty secures earlier payment: Heidelberg Pharma and Healthcare Royalty (HCRx) announced on 13 March 2025 that they had signed an amendment to the original license agreement dated March 2024. Heidelberg Pharma received an immediate payment of USD 20 million upon signing of the agreement. In return, the sales-related milestone of USD 15 million for 2025 no longer applies due to the later potential launch of TLX250-CDx and the originally agreed payment of USD 75 million upon approval of TLX250-CDx by the FDA is reduced to USD 70 million, with further potential reductions if FDA approval occurs after the end of 2025. The basis of consolidation as of the reporting date comprises Heidelberg Pharma AG and Heidelberg Pharma Research GmbH and the two companies established in the previous year, HDP G250 AG & Co. KG and HDP G250 Beteiligungs GmbH. These two companies are affiliated below the parent company Heidelberg Pharma AG, are not operationally active and are each fully consolidated. The reporting period referred to below concerns the period from 1 December 2024 to 28 February 2025 (Q1 2025). In the first three months of fiscal year 2025, the Group generated sales revenue and other income totaling EUR 2.9 million (previous year: EUR 1.9 million). As in the previous year, this includes EUR 1.3 million sales revenue, which in turn largely consists of deferred income in both years. Other income increased by EUR 1.6 million compared to the previous year (EUR 0.6 million) and resulted primarily from a milestone payment in connection with the sale of a minority interest in 2023. Operating expenses, including depreciation, amounted to EUR 9.0 million in the reporting period (previous year: EUR 6.6 million). Cost of sales amounted to EUR 44 thousand and were thus roughly in line with the previous year's figure (EUR 30 thousand). Research and development costs increased as planned to EUR 6.6 million compared to EUR 5.1 million in the same quarter of the previous year and, at 73% of operating expenses, represented the largest cost item. Both periods were characterized by the cost-intensive external manufacturing for the ADC projects and the ongoing clinical study with HDP-101, and this year's period was also influenced by the preparation of the clinical study with HDP-102. Administrative expenses increased to EUR 1.6 million in the first three months of 2025 compared to the prior-year period (EUR 1.2 million). These include, among other things, the costs of holding activities and the stock exchange listing. Other expenses for business development, marketing and everything else increased from EUR 0.2 million in the previous year to EUR 0.7 million, in particular due to foreign currency valuations. The Heidelberg Pharma Group´s net loss increased for the first three months of the fiscal year to EUR 5.9 million compared to the previous year (EUR 4.5 million) as planned. Basic earnings per share based on the weighted average number of shares issued during the reporting period decreased from EUR -0.10 in the previous year to EUR -0.13 in the past quarter as a result of the increased loss. Total assets as of 28 February 2025 amounted to EUR 52.8 million and was below the comparable figure as of 30 November 2024 (EUR 60.7 million) due to the loss for the period as well as reduced liabilities and the associated lower cash. At EUR 25.1 million, equity was also below the figure at the end of the 2024 fiscal year (EUR 30.9 million). This corresponds to an equity ratio of 47.5% (30 November 2024: 50.8%). No corporate actions were carried out during the reporting period. The capital stock of Heidelberg Pharma AG thus remained unchanged at EUR 46,604,977, divided into 46,604,977 no par value bearer shares. At the end of the fiscal quarter, cash amounted to EUR 20.7 million (30 November 2024: EUR 29.4 million). Heidelberg Pharma thus recorded an average cash outflow of EUR 2.9 million per month in the first quarter of the fiscal year (previous year: EUR 3.6 million). Financial outlook for 2025 The Executive Management Board expects the Heidelberg Pharma Group to generate between EUR 9.0 million and EUR 11.0 million in sales revenue and other income in the 2025 fiscal year. If income and expenses develop as anticipated, the change in cash funds in the 2025 fiscal year for Heidelberg Pharma AG’s business operations is expected to improve significantly compared to 2024. The expected cash inflow will be between EUR 50.0 million and EUR 55.0 million in total due to a further HCRx payment. Operating expenses in 2025 are expected to be between EUR 40.0 million and EUR 45.0 million if business develops as planned, and thus roughly at the level of the 2024 reporting year (EUR 32.6 million). An operating result of between EUR -30.0 million and EUR -35.0 million is expected for 2025 (2024: EUR -20.7 million). Based on the current budget, and taking into account an additional expected payment of USD 70.0 million (less transaction costs) from HealthCare Royalty, the Group is funded into 2027. A conference call on this interim management statement will not take place. The complete figures for the interim financial statements can be downloaded from http://www.heidelberg-pharma.com/ ”Press & Investors > Announcements > Financial Reports > Interim statement on the first three months of 2025”. Key figures for the Heidelberg Pharma Group (unaudited) In EUR thsd. Q1 20251 EUR thsd. Q1 20241 EUR thsd. Earnings Sales revenue 1,270 1,267 Other income 1,603 592 Operating expenses (8,991) (6,566) of which research and development costs (6,610) (5,073) Operating result (6,118) (4,707) Earnings before tax (5,938) (4,445) Net loss for the period / Comprehensive income (5,938) (4,494) Earnings per share in EUR (basic) (0.13) (0.10) Balance sheet as of the end of the period Total assets 52,805 61,666 Cash 20,678 32,650 Equity 25,063 45,114 Equity ratio2 in % 47.5 73.2 Cash flow statement Cash flow from operating activities (8,584) (10,748) Cash flow from investing activities (121) (42) Cash flow from financing activities (31) (29) Employees (number) Employees as of the end of the period3 116 111 Full-time equivalents as of the end of the period3 105 98 1 The reporting period begins on 1 December and ends on 28/29 February. 2 Equity / total assets 3 Including members of the Executive Management Board Rounding of exact figures may result in differences.

Debiopharm announces oral and poster presentations on data from their potential first-in-class compound Debio 1562M, a CD37-targeted ADC, and their best-in-class compound Debio 0123, a brain-penetrant WEE1 inhibitor. The company also announces joint poster presentation with new partner on the use of its AbYlink™ technology in preclinical setting. Lausanne, Switzerland – April 22, 2025 – Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases and develop new antibody linker technologies, will release promising new data for two of its pipeline products at the 2025 Annual American Association for Cancer Research (AACR) meeting in Chicago, Illinois. Furthermore, a joint poster presentation with Oncodesign Services (www.oncodesignservices.com) will highlight the applicability of its antibody conjugation technology, AbYlink™, in the preparation of conjugates for use in non-invasive preclinical imaging. Comprehensive preclinical results will be presented for Debio 1562M, a next-generation Antibody-Drug Conjugate (ADC) targeting the cell surface glycoprotein CD37 soon to undergo first-in-human evaluation. Two preclinical data releases will be included in the poster display sessions for Debio 0123, a selective WEE1 kinase inhibitor disrupting the DNA-damage response (DDR) of cancer cells. The first data release shows how Debio 0123 can be used in combination with the PKMYT1 inhibitor lunresertib as a promising therapeutic strategy in ovarian and breast cancer. The company will also unveil new impactful findings stemming from its collaboration with Genialis, showing how machine learning has the potential to enhance the ability to predict responders to Debio 0123, thus further advancing the understanding and application of WEE1 biology and response to inhibitors. Additionally, in the framework of a licensing agreement and a collaborative endeavor to support innovative research, Debiopharm and Oncodesign Services will present promising new data illustrating how AbYlink™ conjugation technology can facilitate the production of conjugates for use in preclinical research in cancer treatment. “The pre-clinical results to be released during the AACR are laying a solid foundation for future research,” explained Angela Zubel, Chief Development Officer, Debiopharm. “The two drug research approaches of ADCs and DDR inhibition are harnessing novel modalities and targets with the potential to outsmart hard-to-treat liquid and solid tumors, revolutionizing patient outcomes. Our AbYlink™ technology demonstrates great potential in the context of antibody radio conjugates against cancer and shows promise for broader use and wider applications.” Poster Session Title: Antibody-Based Cancer Therapeutic Agents – Sun, April 27th Mini symposium: 3:35-3:50pm Abstract Presentation#: 1160 Debiopharm Compound: Debio 1562M Title: Debio 1562M, a 2nd generation ADC targeting CD37, shows high potency against AML and MDS and safe toxicological profile for future clinical development Presenter: Lisa Ivanschitz, Associate Principal Scientist, Debiopharm Poster Session Title: DNA Damage Response and Modulation of DNA Repair 1 – Mon, April 28th Poster display: 2:00-5:00pm Abstract #2914 Poster Section: 16 Poster Board #: 21 Debiopharm Compound: Debio 0123 Title: The WEE1 inhibitor Debio 0123 is synergistic with the PKMYT1 inhibitor lunresertib in preclinical models of ovarian and breast cancer Presenter Luke Piggott,Principal Scientist, Debiopharm Poster Session Title: Artificial Intelligence and Machine Learning for Therapeutic Election and Discovery – Mon, April 28th Poster display: 2:00-5:00pm Abstract #3659 Poster Section: 45 Poster Board #: 21 Debiopharm Compound: Debio 0123 Title: Biology-driven, machine learning-based development of a biomarker to predict response to WEE1 inhibitor Debio 0123 Presenter: Kristian Urh, Genialis Poster Session Title: Radiation Treatment Combinations for Tumors, Normal Tissue – Mon, April 28th Poster display: 9:00am-12:00pm Abstract #1825 Poster Section: 24 Poster Board #: 11 Debiopharm Technology: AbYlink™ Title: Pharmacological evaluation of bioconjugated Trastuzumab using the AbYlink™ regio-selective conjugation technology in gastric cancer expressing HER2+ Presenter: Eftychia Koumarianou, Head of pharmaco-imaging and molecular radiotherapy, Oncodesign Services When cells have damaged DNA, they need to undergo a repair process called DDR to be able to survive. Cancer cells rely a lot on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, which ultimately activates a self-destruction program in cancer cells. DDR inhibitors such as Debio 0123, a WEE1 inhibitor from Debiopharm, are being tested in clinical and preclinical studies. We’re developing fit-for-purpose antibody drug conjugates through a tailored “Trifecta” approach: strategic target selection, innovative Multilink™ linker technology and smart payload choices. Our broad and balanced portfolio of 1st-in-class and best-in-class ADCs includes Debio 0633 (undisclosed target), Debio 1562M, a CD37-targeted ADC for the treatment of acute myeloid leukemia (AML) Myelodysplastic syndromes (MDS), Debio 0532, an HER3-targeted ADC for solid tumors, as well as other ADCs for undisclosed targets including a proprietary bispecific ADC. Key partnerships also comprise options to in-licence bispecific antibodies targeting HER2-HER3 and HER3-EGFR along with other antibodies for undisclosed targets. To allow both high DAR and high stability, our ADCs are designed with our innovative proprietary Multilink™ linker technology. We’re leveraging key collaborations and our in-house capabilities including ADC conjugation, optimization, PK/PD, toxicology, translational medicine, clinical development and supply chain to produce novel ADCs that respond to the high unmet needs of cancer patients. AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use to prepare diagnostic or therapeutic conjugates. This one step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g. a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads. Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential assets and technologies for in- licensing, clinically demonstrate their safety and efficacy, and then select pharmaceutical commercialization partners to maximize patient access globally. Visit www.debiopharm.com/drug-development/ and www.debiopharm.com/manufacturing-science/ Follow us https://www.linkedin.com/company/debiopharminternational/

46% objective response rate, with 15% complete responses and 31% partial responses in patients with early-stage follicular lymphoma reported at the ASH 2024 meeting.Well-tolerated treatment with no severe adverse events.Early CD8+ T cell expansion may predict positive clinical outcomes.Findings support EO2463 as a proactive treatment option for asymptomatic patients who typically go untreated. Paris, France – December 10, 2024 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, today announced new clinical data from the ongoing Phase 1/2 ‘SIDNEY’ trial evaluating EO2463 in patients with indolent Non Hodgkin Lymphoma. The data were presented in two posters at the 66th American Society of Hematology (ASH) Annual Meeting and Conference by Dr. Villasboas Bisneto, M.D., hematologist and oncologist at Mayo Clinic, and Dr. Stephen Smith, M.D., hematologist and oncologist at Fred Hutchinson Cancer Center. Enterome is also holding a webinar on December 12, 2024 for external audiences in order to run through the data sets. See details at the end of this release. The Phase 1/2 SIDNEY trial (EONHL1-20) investigates EO2463, an off-the-shelf immunotherapy targeting four B cell antigens and based on Enterome’s OncoMimic™ peptides, in patients with frequent forms of indolent Non-Hodgkin Lymphoma. In Cohort 2 of the SIDNEY trial, patients with newly diagnosed, asymptomatic follicular lymphoma, received EO2463 monotherapy as an alternative to the standard “watch-and-wait” approach. With most patients still on study treatment, an objective response rate of 46% has been observed in the first 13 patients, including 15% complete responses and 31% partial responses. Consistent with observations from the safety lead-in cohort, the treatment was well tolerated, with no severe adverse events, suggesting EO2463 may offer a safe treatment option for patients with early-stage disease. A biomarker analysis was conducted in Cohort 1 (EO2463 in monotherapy and in combination with lenalidomide/rituximab, in patients with relapsed/refractory disease) to explore whether early CD8+ T cell expansion in response to EO2463 administration could serve as a predictor of later clinical benefit. The current assessment indicates that the biomarker as applied (measuring fast expansion of EO2463 specific CD8 T cells) can predict for clinical response, both for EO2463 monotherapy, and for EO2463 in combination with lenalidomide + rituximab. Jan Fagerberg, Chief Medical Officer of Enterome, commented, “These new data provide encouraging indications that EO2463 can safely induce meaningful responses in patients with newly diagnosed follicular lymphoma typically managed with observation alone, addressing an important unmet need. Additionally, our biomarker findings open up possibilities for precision immunotherapy by identifying patients most likely to benefit early in their treatment course.” Pierre Bélichard, CEO of Enterome, added, “These promising results from Cohort 2 in the SIDNEY trial mark an important step in our commitment to providing early therapeutic options for patients who would usually not receive immediate treatment due to the absence of safe and effective therapies. We look forward to advancing EO2463 through the SIDNEY trial and to expanding our work with OncoMimics™ immunotherapies in other blood cancer types.” Details of the poster presentations: Abstract #1616 Title: EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/RituximabPresenting Author: Jose Caetano (JC) Villasboas, MD Mayo ClinicSession: 622. Lymphomas: Translational – Non-Genetic: Poster I Abstract #4395 Title: EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/SIDNEY StudyPresenting Author: Dr. Stephen Smith, M.D., UW Medicine, Fred Hutchinson Cancer Research CenterSession: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III About EONHL1-20/SIDNEY: SIDNEY (EONHL1-20) is a Phase 1/2 multicenter, open-label, first-in-human study of EO2463 as a monotherapy and in combination with lenalidomide and/or rituximab for the treatment of patients with iNHL. The study aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 monotherapy and combination therapy in approximately 60 patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL). For more information on the study, visit www.Clinicaltrials.gov, reference: NCT04669171. About EO2463: EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimic™ peptides. These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the B lymphocyte-specific lineage markers CD20, CD22, CD37, and CD268 (BAFF receptor). EO2463 also includes the helper peptide (CD4+ epitope) universal cancer peptide 2 (UCP2). The unique ability of EO2463 immunotherapy to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes that are abundant in iNHL. By ensuring broad target coverage across malignant B cells, this novel approach aims to simultaneously improve safety and maximize efficacy, reducing the tumor cells’ capacity to develop immune-resistance mechanisms. Details of the webinar, please register at enterome@vigoconsulting.com to attend. Date: 12 December 2024 Time: 7.30am-8.30am PT / 9.30am-10.30am Central US time / 3.30pm-4.30pm UK / 4.30pm-5.30pm CET Presenters: Jose Caetano (JC) Villasboas, MD Mayo Clinic Pierre Belichard PhD, CEO, Enterome Laurent Chene PhD, Head of Drug Discovery, Enterome Jan Fagerberg, MD, PhD, CMO Enterome Registration link: HERE (https://storm-virtual-uk.zoom.us/webinar/register/WN_jTBLmm7ZRBK6KLvtG3I6Lw) Webinar ID 822 5290 4200 Contacts ENTEROMEMEDIA RELATIONSMarie-Laure BouttierChief Corporate Officer+33 (0)1 75 77 27 85communication@enterome.comVigo ConsultingMelanie Toyne-Sewell / Rozi Morris+44 207 390 0237 / 0231enterome@vigoconsulting.com About Enterome Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body. Enterome’s first-in-class drug candidates are based on synthetically produced, commensal-derived peptides that modulate the immune system by closely mimicking the structure of specific antigens. The company’s oncology pipeline includes the following OncoMimics™ peptide-based immunotherapies: EO2463, currently in the Phase 2 ‘SIDNEY’ clinical trial for indolent non-Hodgkin lymphomas, has shown a favorable safety profile with promising early signs of efficacy;EO2401, administered in combination with nivolumab and bevacizumab, has demonstrated clinical activity in approximately one-third of patients with recurring glioblastoma in the completed Phase 1/2 ‘ROSALIE’ study;EO4010 is being evaluated in metastatic colorectal cancer in the Phase 1/2 ‘AUDREY’ study. Enterome is headquartered in Paris, France. Since its inception, the company has raised a total of €118 million from Europe- and US-based life science investors, and more than €100 million through pharmaceutical partnerships. For more information, please visit the company’s website at: www.enterome.com